Literature DB >> 19739038

Hormones and cardiovascular disease: a shift in paradigm with clinical consequences?

Bregje van Zaane1, Anne Q Reuwer, Harry R Büller, John J P Kastelein, Victor E A Gerdes, Marcel Th B Twickler.   

Abstract

Several endocrine disorders have been associated with an increased risk of cardiovascular disease (CVD) and mortality. In addition, even subtle hormonal disturbances may modulate the function of cardiovascular organs. In this article, we discuss in detail the contribution of thyroid hormones, cortisol, the somatotropic hormones, and prolactin in the development of CVD. We do not only discuss epidemiological evidence on the association between hormones and cardiovascular disease, but we also address possible pathophysiological mechanisms underlying this association. In fact, hormones can contribute to the development of CVD both indirectly by inducing secondary metabolic changes such as hypertension, insulin resistance, or dyslipidemia, and directly by modulation of cellular pathways that are important in the process of atherosclerotic plaque formation (atherogenesis), plaque instability, and thrombosis. To date several new therapeutic approaches that focus on the control of hormones at the tissue level, independently of their circulating levels, are being developed. These may offer new possibilities for cardiovascular risk reduction. Copyright Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19739038     DOI: 10.1055/s-0029-1234143

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  4 in total

Review 1.  Pathophysiological basis of cardiovascular disease and depression: a chicken-and-egg dilemma.

Authors:  Gilberto Paz-Filho; Julio Licinio; Ma-Li Wong
Journal:  Braz J Psychiatry       Date:  2010-06       Impact factor: 2.697

2.  Plasma osteoprotegerin is associated with testosterone levels but unaffected by pioglitazone treatment in patients with polycystic ovary syndrome.

Authors:  D Glintborg; A P Hermann; L M Rasmussen; M Andersen
Journal:  J Endocrinol Invest       Date:  2012-11-26       Impact factor: 4.256

3.  Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study.

Authors:  Anne Q Reuwer; Brigitte M Sondermeijer; Suzanne Battjes; Rogier van Zijderveld; Danka J F Stuijver; Peter H Bisschop; Marcel Th B Twickler; Joost C M Meijers; Reinier O Schlingemann; Erik S Stroes
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

4.  Thioredoxin interacting protein is a potential regulator of glucose and energy homeostasis in endogenous Cushing's syndrome.

Authors:  Tove Lekva; Jens Bollerslev; Afaf Sahraoui; Hanne Scholz; Hege Bøyum; Johan Arild Evang; Kristin Godang; Pål Aukrust; Thor Ueland
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.